期刊名称：JOURNAL OF PAIN RESEARCH
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
An international, peer-reviewed, open access, online journal that welcomes laboratory and clinical findings in the fields of pain research and the prevention and management of pain. Original research, reviews, symposium reports, hypothesis formation and commentaries are all considered for publication.
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE).
Journal Impact Factor: 2.363
Indexed online: 
- PubMed and PubMed Central (J Pain Res)
- Science Citation Index Expanded (also known as SciSearch®)
- Journal Citation Reports/Science Edition
- Embase, from 2009 (Correct as at December 8, 2016)
- Scopus, from 2009 (Correct as at December 8, 2016)
- Directory of Open Access Journals (DOAJ)
- OAIster - The Open Access Initiative
Instructions to Authors
Author Guidelines
- a campaign to provide guidance for researchers when deciding which journal to publish their research in.
Preparation of Manuscript
Include:
- Forename(s) and surnames of authors (see Authorship section below)
- Author affiliations: department, institution, city, state, country
- Abstract 300 words
- Plain language summary (optional)
- 3–6 keywords
- Running header (shortened title)
- Corresponding author: name, physical address, phone, fax, email
- Reference list
- Page numbers
- Clear concise language
- American spelling
- Ensure tables and figures are cited
- The preferred electronic format for text is Microsoft Word
- Manuscripts will be accepted in LaTeX as long as the native LaTeX and a PDF is also supplied
- Use International Systems of Units (SI) symbols and recognized abbreviations for units of measurement
- Do not punctuate abbreviations eg, et al, ie
- Spell out acronyms in the first instance in the abstract and paper
- Word counts are not specified. In general, shorter items range from 1000 to 3000 words and reviews from 3000 to 7,500
- Generic drug names are used in text, tables, and figures
- Suppliers of drugs, equipment, and other brand-name material are credited in parentheses (company, name, city, state, country)
- If molecular sequences are used, provide a statement that the data have been deposited in a publicly accessible database, eg, GenBank, and indicate the database accession number.
While the editors fully understand the extra challenges posed to authors whose native language is not English, we must ask that all manuscripts be reviewed and edited by a native speaker of English with expertise in that area prior to submission.
Authorship
Authorship credit should be based on:
1) Substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data;
2) Drafting the article or revising it critically for important intellectual content;
3) Final approval of the version to be published; and
4) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Authors should meet conditions 1, 2, 3, and 4.
Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship.
All persons designated as authors should qualify for authorship, and all those who qualify should be listed.
Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.
Increasingly, authorship of multicenter trials is attributed to a group. All members of the group who are named as authors should fully meet the above criteria for authorship/contributorship.
When a large, multicenter group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript (3). These individuals should fully meet the criteria for authorship/contributorship defined above, and editors will ask these individuals to complete journal-specific author and conflict-of-interest disclosure forms. When submitting a manuscript authored by a group, the corresponding author should clearly indicate the preferred citation and identify all individual authors as well as the group name. Journals generally list other members of the group in the Acknowledgments. The NLM indexes the group name and the names of individuals the group has identified as being directly responsible for the manuscript; it also lists the names of collaborators if they are listed in Acknowledgments.
The group should jointly make decisions about contributors/authors before submitting the manuscript for publication. The corresponding author/guarantor should be prepared to explain the presence and order of these individuals. It is not the role of editors to make authorship/contributorship decisions or to arbitrate conflicts related to authorship.
Changes to authorship
Dove does not permit the changing/adding/deleting of authors after submission of the paper.
Contributors Listed in Acknowledgments
All contributors who do not meet the criteria for authorship should be listed in an acknowledgments section. Examples of those who might be acknowledged include a person who provided purely technical help, writing assistance, or a department chairperson who provided only general support. Authors should declare whether they had assistance with study design, data collection, data analysis, or manuscript preparation. If such assistance was available, the authors should disclose the identity of the individuals who provided this assistance and the entity that supported it in the published article. Financial and material support should also be acknowledged.
Groups of persons who have contributed materially to the paper but whose contributions do not justify authorship may be listed under such headings as “clinical investigators” or “participating investigators,” and their function or contribution should be described—for example, “served as scientific advisors,” “critically reviewed the study proposal,” “collected data,” or “provided and cared for study patients.” Because readers may infer their endorsement of the data and conclusions, these persons must give written permission to be acknowledged.
Please note: the Authorship and “Contributors Listed in Acknowledgments” sections are reprinted from the ICMJE Uniform Requirements for Manuscripts Submitted to Biomedical Journals. Dove Medical Press prepared this reprint. The ICMJE has not endorsed nor approved the contents of this reprint. The official version of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals is located at http://www.icmje.org/. Users should cite this official version when citing the document.
Authorship: Common issues
Number of authors:
Consideration should be given to the number of qualified authors needed to take responsibility for the publication. To some extent, this will depend on the complexity of the research and of the publication, but it would be unusual in biomedical research (with few exceptions) to require >10 authors to meet this need. A high number of authors calls into question whether they could all have provided "substantial intellectual contribution." Fewer authors are often preferable, and others can be acknowledged (e.g., as nonauthor contributors or collaborators).
Author sequence:
Authors should decide how this will be determined at the initiation of the work, including the designation of the lead and corresponding authors, who may or may not be the same person. Final order, however, should be based on authors' actual roles and contributions in the development of the publication (and therefore cannot be agreed upon until this in complete). Those who made the greatest contribution are generally listed first, but alphabetical order may also be used. It may be useful to describe in the contributorship section of the publication whether alphabetical order or some other convention was used to determine author order.
Addition or removal or author:
In certain circumstances during the development of a publication, it may be necessary to add or remove an author (e.g., if an author fails to provide a substantial contribution or approve the final version of the work). In such cases, all authors should agree to the change. Only in rare cases, such as the work substantially changing in response to reviewer comments, should addition or removal of an author be considered after submission.
Death or incapacity of an author:
Should an author die after completing a major part of the work, posthumous authorship can be considered if agreed to by all other authors. We suggest, as a first step, seeking advice on correct attribution and process from journal instructions or the editorial office.
If the journal agrees to posthumous authorship but requires submission forms to be signed, then in the case of a sponsor-employed author or a contractor, a supervisor may be the most appropriate proxy. Otherwise, a family member or person with power of attorney should be approached. In all cases, efforts should be made to contact the family of the deceased author to inform them of the intention and request their consent to the listing or acknowledgment.
Change of affiliation:
If an author changes affiliation before the work is published, his or her affiliation should reflect where the major part of the work was done. The current affiliation and contact details should be listed in a footnote or in the acknowledgment section. Change of affiliation alone is not a valid reason to remove an author from a publication if he or she meets authorship criteria.
Company- or sponsor-employed authors:
Sponsor-employed scientists and clinicians are often qualified to participate as authors of company-sponsored research publications and should have that opportunity. Such authors should not be denied authorship because of concerns about perception of bias. Whatever criteria are used to determine authorship should be applied equally to company employees, contractors, and others.
Professional writers as authors:
Professional medical writers who meet applicable authorship criteria should be listed as authors. If writers do not meet authorship criteria, their contribution should be disclosed (e.g., as a nonauthor contributor in the acknowledgment section). Writers who were not involved with study design, data collection, or data analysis and interpretation (e.g., those developing a primary publication from a clinical study report) generally do not meet International Committee of Medical Journal Editors authorship criteria. However, professional writers working on other types of publication (e.g., literature reviews) may qualify as authors.
Please note: The "Authorship: Common issues" section was adapted from Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, et al. Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3. Ann Intern Med. 2015;163:461-464. doi:10.7326/M15-0288 Appendix Table 2. Common Issues About Authorship.
Related Authors
Where authors of a paper are related this should be disclosed at the time of submission. Please provide details of the family relationship between such authors.
Figures and Tables
- Submit as separate files and also as one combined file
- Submit figures as JPG files
- Number consecutively
- Provide a descriptive heading/legend
- Place abbreviations immediately below the table
- Use superscript a, b, c… as identifiers
- Supply Line Art 900 dpi, Combination (Line Art + Halftone) 900 dpi, Halftone 300 dpi
- Graphics downloaded from Web pages are NOT acceptable
- Submit multi-panel figures, ie with parts labeled a,b,c,d, as one file
Plain Language Summary
Academic articles are generally written in a specific manner and aimed at communities of experts. It can be extremely difficult for lay audiences or people not familiar with the field of study to understand those articles.
One way to bridge the gap between providing open access to knowledge and improving its understanding is to provide an easily understandable, stand-alone plain language summary alongside the published research article. As Professor Sir Mark Walport said “Science is for everyone. It’s not just to be shared within a small, closed community. We are in the middle of an information revolution, which has been made possible by Open Access and electronic publications. Plain-English summaries are the way of the future” (Keynote speech, Access to Understanding competition awards ceremony 2014).
Not only is it useful for researchers to write plain language summaries of their articles to make them accessible to a wider audience but they can also make research accessible to professionals in nearby disciplines. Crucially, plain language summaries are beneficial to improve public engagement with science and medical research. By helping the public to understand biomedical research, researchers can contribute to raising awareness of its value and attracting further public support and involvement. Plain language summaries can help connect researchers with those, who are directly and indirectly impacted by the outcomes of the research thereby helping scientists understand the needs of patients, carers, health professionals, and other members of the public. In turn, better understanding of biomedical research can inform future research directions and funding priorities as well as increase recruitment to clinical trials.
The plain language summary should have between 150-200 words, be written in plain English, and placed between the Abstract and Introduction of your manuscript (before the keywords). Provide answers to the questions: Why was the study done? What did the researchers do and find? What do these results mean?
Supplementary Data
Any supplementary data should be kept to 4 typeset pages or 2,400 words. If you have any more than this you should provide a link to the supplementary data on an external website, your institute’s website for example, and/or Dove Medical Press may be able to upload the raw supplementary data to the http://www.dovepress.com/ website and provide a link in your paper. We welcome video files either as supplementary data or as part of the actual manuscript to show operations, procedures, etc.
Use of Brand Names in submitted manuscripts
We require that generic drug names are used in submissions. When proprietary brands are used in research, use the generic name throughout the text. You may include the brand name(s) in parentheses after the first mention only of the generic name.
Clinical Trial Registration
We require the registration of all clinical trials in a public trials registry at or before the time of first patient enrollment.
Letter to the Editor
Letters to the Editor will be considered for publication that are pertinent to articles recently published in Dove Medical Press (DMP) journals. Please ensure that your letter is addressed to the appropriate Editor-in-Chief of the journal concerned. All letters should be received within 30 days of the published paper appearing in a DMP journal. Letters received after this time will rarely be considered. All letters will be screened for appropriateness and significance and the Editor may assign external peer review at their discretion. DMP journals are not a vehicle for grievances or personal rebukes. DMP reserves the right to reject letters where the Editor-in-Chief has deemed it unfit on the grounds of misleading, inaccurate or inappropriate content. The Editor-in-Chief will make a final decision. Word count should not exceed 500 words of text and 5 references, 1 of which should be to the recent article, and no more than 3 cited authors. The text should include the full name, academic degrees, and a single institutional affiliation for each author and the e-mail address for the corresponding author. Letters should not duplicate other material published or submitted for publication and should not include unpublished data. Letters not meeting these specifications are generally not considered for publication.
Research Letter
Research Letters are concise, focused reports of original research or observations. They should not be under consideration, submitted or published elsewhere in any form, in part or as whole. They should not exceed 600 words of text and 7 references, and up to 2 tables or figures/photographs/images (photograph format should follow research article guidelines – see Figures and Tables). An abstract is not required for a Research Letter but authors should follow the manuscript preparation and submission guidelines. Research letters are subject to external peer review. The Editor-in-Chief of the journal will make the final decision on publication. Research Letters not meeting these specifications are generally not considered for publication.
Photo Essays
Manuscripts submitted as a Photo Essay should focus on the visual aspects of the topic presented. It should be a series of photographs that visually tell the story the author wishes to convey. The photos should be self-explanatory of very high quality. Photographs can be of clinical subjects, laboratory results (eg, slides, scans, magnetic resonance images, ultrasonograms) and therapeutic procedures. A Photo Essay should not exceed 300 words and should have no more than 10 references. The number of photographs is limited to 10, with a limit of 60 words for each legend. Please note that not all journals published by Dove Medical Press accept Photo Essays, please ask before submitting.
Submission of Manuscript
- All manuscripts should be submitted via our website.
- By doing so you agree to the terms and conditions of submission
- Keep a backup and hard copies of the material submitted
Pre-submissions
- Authors are welcome to send an abstract of their manuscript to obtain a view from the Editor about the suitability of their paper. Please complete the pre-submission check form here. Our Editors will do a quick review (not peer review) of your paper and advise if they believe it is appropriate for submission to their journal. It will not be a full review of your manuscript.
Reference Style
See Reference Style Guidelines
Proofs
- You will receive the typeset page proofs for approval
- Check amendments made by the editor have not rendered the material inaccurate
- Check you have answered all the editor’s queries
- Ensure your corrections are minimal and absolutely necessary
- Mark the adjustments clearly in the text and margins, and keep a copy of what you send to the editor
- Notify the editorial office of all corrections within 72 hours of your receipt of the material
- Ensure all authors sign and return the Approval for Publication and final page of Publication Agreement
All Dove journals are members of and subscribe to the principles of the Committee on Publication Ethics (COPE).
We also support the international standards for editors and authors that were developed at the 2nd World Conference on Research Integrity in Singapore in 2010.
Rejection Rate
For 2016 the total of rejections/withdrawals across all Dove journals was 53%. This was 47% in 2015 and 42% in 2014.
Updated 12 January 2017
Editorial Board
Dr Schatman
Director of Research, U.S. Pain Foundation, Adjunct Clinical Assistant Professor, Tufts School of Medicine, United States
Editor-in-Chief: Dr. Michael E Schatman Ph.D., CPE
Dr. Schatman is a clinical psychologist who has spent the past 30 years working in multidisciplinary chronic pain management. He is currently the Director of Research of the U.S. Pain Foundation in Bellevue, WA and Middletown, CT, and serves on the teaching faculty at Tufts School of Medicine’s Department of Public Health & Community Medicine in Boston, MA.
Dr. Schatman is the author of over 100 journal articles and book chapters on various aspects of chronic pain management, and lectures regularly on pain management on local, national and international bases. He is also the editor of Ethical Issues in Chronic Pain Management and Chronic Pain Management: Guidelines for Multidisciplinary Program Development, both of which were released by Informa Healthcare in 2007. Dr. Schatman is on the editorial review boards of the Journal of Pain, Pain Medicine, Pain Practice, Pain & Therapy, the World Journal of Anesthesiology and Psychological Injury & Law, serving as the Ethics Forum co-Editor of Pain Medicine and as the Ethics co-Section Head of Psychological Injury & Law. He is the Secretary of the Western Pain Society, resurrected and served as the Chairperson of the Ethics Special Interest Group of the American Pain Society from 2008-2013, is a member of the Ethics Committee of the American Pain Society, the Ethics Council of the American Academy of Pain Medicine, and is on the Board of Directors of the American Society of Pain Educators – which named him 2011 Clinical Pain Educator of the Year.
Dr Hanlon
Biomedical Sciences, University of New England COM, United States
Associate Editor in Chief
Associate Editor: Katherine Hanlon
Dr. Katherine Hanlon is a Rita Allen Foundation scholar and assistant professor at the University of New England College of Osteopathic Medicine in Biddeford, ME. Dr. Hanlon received a B.S. in Biochemistry and Molecular Biophysics followed by a Ph.D. in Pharmacology at the University of Arizona. The Hanlon lab explores macrophage differentiation and function in biological systems with a particular focus on the functional implications of neuro-immune communication between neuronal cell bodies and tissue resident macrophages in the dorsal root ganglia as it pertains to nociception. Proinflammatory mediators released by peripheral immune cells contribute to the sensitization of nociceptors in response to injury, suggesting that modification of immune cell activity may alter plasticity and ultimately the perception of persistent pain. The Hanlon lab is working to target macrophages in to develop novel non-opioid targets for the treatment of pain.
A distinct but equally important point of focus in the Hanlon laboratory relates to modulation of tumor associated macrophage function in breast cancer. These are novel and timely investigations contributing to a growing body of research indicating that the need for toxic chemotherapeutic regimens may be lessened with the addition of immunomodulating compounds. To date, tumor associated macrophages (TAMs) have been incompletely studied as a potential immunomodulatory target to improve disease outcome, despite the demonstrated contribution of TAMs to tumor development. The Hanlon lab investigates novel pathways in the modulation of TAMs with the goal of developing novel therapeutics for the treatment of breast cancer and other solid tumors.
Dr Robinson
Psychiatry, University of Texas Southwestern Medical Center, United States
Associate Editor in Chief
Associate Editor: Richard Robinson
University of Texas Southwestern Medical Center, Dallas, TX, USA
Dr Romero-Sandoval
Pharmaceutical and Administrative Sciences, Presbyterian College School of Pharmacy, United States
Associate Editor in Chief
Associate Editor: E. Alfonso Romero-Sandoval
Dr. Romero-Sandoval received an M.D. from the Centro Universitario de Occidente, Quetzaltenango (Universidad de San Carlos de Guatemala) in 1999 and a Ph.D. in Neuroscience from Universidad de Alcalá de Henares, Spain, in 2003. His postdoctoral training was completed at Wake Forest University, Winston Salem, NC (2003-2006) followed by Geisel Dartmouth Medical School, Lebanon, NH (2006-2007).
Dr. Romero-Sandoval has held academic positions as Instructor (2007-2009) and Assistant Professor (2009-2012) at Geisel Dartmouth Medical School. Currently (2012-present) he is an Associate Professor and the Director of Research at Presbyterian College School of Pharmacy in Clinton, SC.
Dr. Romero-Sandoval studies the molecular mechanisms of cannabinoid receptor activation in skin and immune cells in the induction of analgesia, resolution of inflammation, and promotion of tissue repair. The Romero-Sandoval laboratory explores the role of endocannabinoids in postoperative pain and its transition to persistent postoperative pain in addition to the function of phosphatases and kinases in spinal cord and the peripheral nervous system. Most recently Dr. Romero-Sandoval has focused on elucidating the role of macrophages in wound healing and the transition from acute to chronic pain in the context of diabetic neuropathy or surgical pain. The ultimate goal of the Romero-Sandoval lab is to restore the molecular mechanisms and cellular functions that are altered under pathological inflammatory and painful conditions. The Romero-Sandoval laboratory uses highly translatable clinical approaches such as the use of human primary cells, the use of clinically relevant functional assays, and the use of clinically tested nanotechnology for potential cell-directed gene therapies.
Prof. Dr. Santarcangelo
Department of Translational Research, University of Pisa, Italy
Associate Editor in Chief
Associate Editor: Dr Enrica Laura Santarcangelo
Dr. Enrica Laura Santarcangelo, MD, PhD, clinical psychologist, is an Associate Professor of Physiology at the Department of Translational Research and New Technologies in Medicine and Surgery, Pisa University. She is interested in the physiology of the mind-body axis and, in particular, in the physiological correlates of hypnotizability in the sensori-motor and cardiovascular domain. Findings in these fields allow us to consider the susceptibility to hypnosis as a factor of variability of the general healthy population in the ordinary state of consciousness and in the absence of specific suggestions. In the subjects with high hypnotizability scores Dr. Santarcangelo has shown a less strict cerebellar control of posture and movement, a higher parasympathetic component of heart rate variability and greater availability of endothelial nitric oxide, whose release is not reduced by stress and acute pain. In the field of pain, she has contributed that suggestions of analgesia are effective also out of hypnosis and that, in line with the earliest findings of KE Hilgard, the modulation of pain perception is not always associated with congruent autonomic changes. In addition, she has shown that other cognitive-emotional traits such as those based on the activity of Grey’s Behavioral Approach/inhibition System interact with hypnotizability in determining the efficacy of pain imagery, pain modulation and its cortical correlates.
Editorial Board
Phillip J. Albrecht, Vice-President, Integrated Tissue Dynamics, Rensselaer, NY, USA
Yoichi Aota, MD. Vice President. Yokohama Brain & Spine Center, Japan
Ruth Arnon, Professor, Weizmann Institute of Science, Israel
Amina Barkat, Professor, Chief of Medicine & Neonatal Resuscitation, National Reference Centre of Neonatology & Nutrition, Children's Hospital of Rabat, University Mohammed V Souissi Rabat, Rabat, Morocco
Abdulbari Bener, Advisor to WHO, Professor of Public Health, Dept. of Biostatistics & Medical Informatics, Cerrahpaşa Faculty of Medicine, Istanbul University, Turkey
Professor Caudle
United States
Robert Caudle, Professor, Department of Oral, Maxillofacial Surgery and Diagnostic Sciences, University of Florida College of Dentistry, FL, USA
Rupert Conrad, Department of Psychosomatic Medicine and Psychotherapy, Bonn University Hospital, Germany
Gabriele Finco, Professor, Full Professor of Anesthesiology and Intensive Care, Department of Medical Sciences "M. Aresu", University of Cagliari, Cagliari, Italy
Professor Gatchel
United States
Robert J Gatchel, Professor, Department of Psychology, College of Science, University of Texas at Arlington, TX, USA
Professor Gold
United States
Michael S. Gold, PhD, Department of Neurobiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
Mitch Haas, Professor, Associate Vice President of Research, University of Western States, Portland, OR, USA
Dr Iannitti
United Kingdom
Tommaso Iannitti, Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK
Yuichi Kasai, Professor, Department of Spinal Surgery and Medical Engineering, Mie University Graduate School of Medicine, Mie, Japan
Dr Keppel Hesselink
Netherlands
Jan M Keppel Hesselink, Professor Molecular Pharmacology,Institute for Neuropathic Pain, Bosch en Duin, The Netherlands and Department of Medicine, University of Witten Herdecke, Witten, Germany
Igor Kissin, Professor of Anaesthesia, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
Halina Machelska, Professor, Klinik für Anaesthesiologie und operative Intensivmedizin, Charité-Universitätsmedizin, Berlin, Germany
Professor Martin
Australia
Paul Martin, Professor, School of Applied Psychology, Psychiatry and Psychological Medicine, Griffith University, Queensland, Australia
Laurent Misery, Professor, Head of Department of Dermatology, University Hospital of Brest, Brest, France; Director of the Laboratory of Neurosciences, University of Western Brittany, Brest, France
Anne Z Murphy, Associate Professor, Associate Director, Neuroscience Institute, Georgia State University, Atlanta, GA, USA
Srinivas Nalamachu, President and Medical Director, International Clinical Research Institute Inc., and Co-Director, Pain Management Institute, Overland Park, KS, USA
Yolanda Rios, Professor, Centro de Investigaciones Químicas, Universidad Autónoma del Estado de Morelos, MS, México
Professor Sabatowski
Germany
Rainer Sabatowski, Professor, Comprehensive Pain Center, Technical University Dresden, Medical Faculty, Dresden, Germany
Jennifer Steel, Department of Surgery, University of Pittsburgh School of Medicine, PA, USA
Richard J. Traub, Ph.D., Professor and Vice Chair, Department of Neural and Pain Sciences, School of Dentistry; Program in Neuroscience; UM Center to Advance Chronic Pain Research; University of Maryland, Baltimore, MD, USA
Dr Weinberg
United States
Jeffrey Mitchell Weinberg, Associate Clinical Professor of Dermatology, Mount Sinai School of Medicine, New York, NY, USA
Ting Xia, Palmer Center for Chiropractic Research, Palmer College of Chiropractic, Davenport, IA, USA
Guogang Xing, Department of Neurobiology, Neuroscience Research Institute, Peking University
Xiaoshu Zhu, University of Western Sydney, NSW, Australia
|
